Please login to the form below

Not currently logged in
Email:
Password:

Iressa

This page shows the latest Iressa news and features for those working in and with pharma, biotech and healthcare.

FDA approval gained, Pfizer sets sights on first-line NSCLC market

FDA approval gained, Pfizer sets sights on first-line NSCLC market

The second-generation EGFR tyrosine kinase inhibitor has been shown in trials to be more effective that first-generation drugs such as AstraZeneca’s Iressa (gefitinib) and Roche’s Tarceva (erlotinib) ... It showed that dacomitinib extended progression

Latest news

More from news
Approximately 6 fully matching, plus 67 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    2016 saw GlaxoSmithKline (GSK) slash the price of its hepatitis drug Viread by two-thirds, and AstraZeneca halved the price of cancer drug Iressa, leading to a 16% decline in sales.

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients with the EGFR mutation. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance mechanism to

  • Payer focus in the personalised world of oncology and orphan diseases Payer focus in the personalised world of oncology and orphan diseases

    more effective (eg Herceptin in HER2+ breast cancer, Iressa and Tarceva in EGFR mutation+ non-small cell lung cancer and Glivec in Philadelphia chromosome+ CML).

  • Market access opportunities in China Market access opportunities in China

    In part as a result of these efforts, both Tarceva and Iressa have been appraised in the Guideline for Diagnosis and Treatment of Primary Lung Cancer published by the Ministry of

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics